Dear Mr. Fallon:
The U.S. Food and Drug Administration (FDA) has completed an evaluation of your firmโs corrective actions in response to our warning letter, WL # NYK-2016-23, dated February 1, 2016. We acknowledge that your firm no longer produces sterile drug products. Based on our evaluation, it appears that you have adequately addressed the violations contained in this warning letter.
You are expected to take all necessary steps to assure compliance with the Federal Food, Drug, and Cosmetic Act and FDAโs implementing regulations. This letter will not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely, /S/ Diana Amador-Toro Program Division Director OPQO Division 1 New Jersey District Office